Signs Of R&D Progress For GSK, Though China Overhang Remains
This article was originally published in PharmAsia News
Executive Summary
With four new drug approvals notched under its belt in four months, GlaxoSmithKline had several potential growth drivers to highlight during its third quarter earnings call, helping to deflect attention away from the bribery scandal in China.
You may also be interested in...
GSK Set For Breo Launch, But Access Will Require Time
GlaxoSmithKline will launch its once-daily COPD treatment Breo in the U.S. in October, Senior VP-Respiratory Jorge Bartolome said in an interview. The company will market Breo as the first once-daily ICS/LABA combination offering 24-hour lung function improvement. But already some payers are denying coverage.
Advair Generics Likely Lucrative Product For Few That Can Clear High Bar
With release of draft bioequivalence guidance for GSK’s blockbuster asthma and COPD treatment, generics seem more likely than ever, but there may be only a select number of companies who can meet the guidance’s requirements.
GSK’s Anoro Ellipta Needs CV Postmarket Study, FDA Panel Says In Endorsement
Pulmonary-Allergy Drugs Advisory Committee votes in favor of what could become the first-approved LAMA/LABA combo for COPD but wants postmarket safety study in patients with more severe cardiovascular disease.